1-9 of 9
Nyla A. Heerema
Close
Sort by
Journal Articles

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

Clinical Trials & Observations
Sheng F. Cai, Ying Huang, Jennie R. Lance, Hsiaoyin Charlene Mao, Andrew J. Dunbar, Samantha N. McNulty, Todd Druley, Yan Li, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti Patel, Matthew C. Foster, Michael Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy L. Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 429–440.
https://doi.org/10.1182/bloodadvances.2023010563
Published: 2024
Includes: Supplemental data
Journal Articles

Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization

Samantha M. Teierle, Ying Huang, Adam S. Kittai, Seema A. Bhat, Michael Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R. Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia R. Miller
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7239–7242.
https://doi.org/10.1182/bloodadvances.2023010753
Published: 2023
Includes: Supplemental data
Journal Articles

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories

Clinical Trials & Observations
Uma Borate, Fei Yang, Richard Press, Amy S. Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C. Pavlick, Luke Juckett, Brianna Norris, Taylor Bucy, Amy Burd, Eytan M. Stein, Prapti Patel, Maria R. Baer, Wendy Stock, Gary Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Mona Stefanos, Brian Druker, John C. Byrd, Ross L. Levine, Alice Mims
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6048–6054.
https://doi.org/10.1182/bloodadvances.2022009008
Published: 2023
Includes: Supplemental data
Journal Articles

Pevonedistat with azacitidine in older patients with TP53 -mutated AML: a phase 2 study with laboratory correlates

Clinical Trials & Observations
Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, James M. Foran
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2360–2363.
https://doi.org/10.1182/bloodadvances.2022008625
Published: 2023
Includes: Supplemental data
Journal Articles

VpreB surrogate light chain expression in B-lineage ALL: a report from the Children’s Oncology Group

Stuart S. Winter, Amanda McCaustland, Chunxu Qu, No’eau Simeona, Nyla A. Heerema, Andrew J. Carroll, Brent L. Wood, Gabriela Gheorghe, Charles G. Mullighan, Bridget S. Wilson
Journal: Blood Advances
Blood Adv (2022) 6 (2): 585–589.
https://doi.org/10.1182/bloodadvances.2021005245
Published: 2022
Includes: Supplemental data
Journal Articles

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group

Clinical Trials & Observations
Yousif Matloub, Karen R. Rabin, Lingyun Ji, Meenakshi Devidas, Johann Hitzler, Xinxin Xu, Bruce C. Bostrom, Linda C. Stork, Naomi Winick, Julie M. Gastier-Foster, Nyla A. Heerema, Eileen Stonerock, William L. Carroll, Stephen P. Hunger, Paul S. Gaynon
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1647–1656.
https://doi.org/10.1182/bloodadvances.2019032094
Published: 2019
Includes: Supplemental data
Journal Articles

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Clinical Trials & Observations
John C. Byrd, Amy S. Ruppert, Nyla A. Heerema, Alese E. Halvorson, Eva Hoke, Mitchell R. Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael J. Thirman, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, Richard A. Larson
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1705–1718.
https://doi.org/10.1182/bloodadvances.2017015396
Published: 2018
Includes: Supplemental data
Journal Articles

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

Clinical Trials & Observations
Tracy E. Wiczer, Lauren B. Levine, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, Amy S. Ruppert, Kerry Rogers, Anli McCoy, Luay Mousa, Avirup Guha, Nyla A. Heerema, Kami Maddocks, Beth Christian, Leslie A. Andritsos, Samantha Jaglowski, Steven Devine, Robert Baiocchi, Jennifer Woyach, Jeffrey Jones, Michael Grever, Kristie A. Blum, John C. Byrd, Farrukh T. Awan
Journal: Blood Advances
Blood Adv (2017) 1 (20): 1739–1748.
https://doi.org/10.1182/bloodadvances.2017009720
Published: 2017
Includes: Supplemental data
Journal Articles

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib

Clinical Trials & Observations
Cecelia R. Miller, Amy S. Ruppert, Nyla A. Heerema, Kami J. Maddocks, Jadwiga Labanowska, Heather Breidenbach, Gerard Lozanski, Weiqiang Zhao, Amber L. Gordon, Jeffrey A. Jones, Joseph M. Flynn, Samantha M. Jaglowski, Leslie A. Andritsos, Kristie A. Blum, Farrukh T. Awan, Kerry A. Rogers, Michael R. Grever, Amy J. Johnson, Lynne V. Abruzzo, Erin K. Hertlein, James S. Blachly, Jennifer A. Woyach, John C. Byrd
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1584–1588.
https://doi.org/10.1182/bloodadvances.2017007302
Published: 2017
Includes: Supplemental data